Can you have heart disease with a zero calcium score? | Dr. Campbell Rogers | EP#426
Dr. Campbell Rogers explains that a zero calcium score indicates low cardiovascular risk but does not rule out coronary disease, as non-calcified plaque can exist undetected. He discusses the emerging role of AI-driven CT angiogram analysis for high-risk patients and those with any detectable coronary calcium, and argues that cardiology is moving toward treating actual plaque visualized on imaging rather than relying solely on biomarker numbers.
Summary
Dr. Rogers clarifies two distinct conclusions that patients often conflate regarding a zero calcium score. While a calcium score of zero does impart very low risk of heart attack, stent placement, or cardiac death based on large clinical studies, it does not mean the patient is free of coronary disease. Non-calcified plaque can exist in coronary arteries but remains invisible to calcium scoring, creating a potential gap in risk assessment.
Regarding the use of CT angiography with AI analysis, Rogers identifies several ideal candidate populations. The clearest indication is symptomatic patients without acute illness, which is Class 1A guideline recommendation. For asymptomatic patients, he identifies high-risk occupational groups (pilots, first responders) as potential candidates. More significantly, any patient with detectable coronary calcium—even scores as low as 5 to 10—has coronary disease and may benefit from detailed plaque assessment via CT angiography, particularly in the ambiguous middle range of calcium scores (1-300) where treatment guidelines show less clarity.
Rogers emphasizes an important clinical application: using imaging to improve medication adherence. Since conditions like high cholesterol and hypertension are abstract to patients who cannot feel or see them, showing patients their actual coronary plaque on imaging can motivate compliance with medical therapy and lifestyle modifications.
On the broader direction of cardiology, Rogers argues the field is moving toward personalized, imaging-based treatment rather than relying exclusively on biomarkers like apoB or LDL levels. He acknowledges significant individual variation—some people with elevated apoB develop disease while others do not—and suggests that direct visualization of plaque burden provides more actionable information. However, he emphasizes the need for continued clinical evidence to support this paradigm shift before compelling widespread adoption among patients, physicians, and guideline writers.
Key Insights
- A zero calcium score imparts very low cardiovascular risk based on large studies, but does not indicate the absence of coronary disease, as non-calcified plaque can exist undetected by calcium scoring
- Any detectable coronary calcium, even scores of 5 to 10, indicates the patient has coronary disease and may warrant detailed plaque assessment via CT angiography
- In the calcium score range of 1 to 300, there is substantial subjectivity in treatment guidelines about medical therapy intensity, whereas scores above 300-400 have more aggressive consensus recommendations
- Visualizing actual coronary plaque on imaging can improve patient medication adherence better than discussing abstract biomarker numbers, as patients cannot feel or see conditions like high cholesterol
- Cardiology is moving toward treating actual visualized plaque rather than relying solely on biomarkers, because individual variation exists where some people with elevated apoB develop disease while others do not
Topics
Transcript
[0:00] What would you say to the person who's had a coronary artery calcium score done and it was zero? And so they have been led to believe that means that they're a very low risk of cardiovascular disease and don't have atherosclerosis. Is that the case and is there a value in someone with a coronary artery calcium score of zero doing this AI-driven analysis of a CT angiogram? >> I would separate the two conclusions you [0:32] just posited. One is they have very low risk and the second is they don't have coronary disease cuz I'll answer those two differently as conclusions from a calcium score of zero. Calcium score of zero does impart very low risk.…
Full transcript available for MurmurCast members
Sign Up to AccessMore from The Proof with Simon Hill
MASH vs. MASLD: Which Medications Are Actually FDA Approved for Weight Loss? | Dr Mauricio Gonzalez
Dr. Mauricio Gonzalez clarifies that the United States has two FDA-approved medications specifically for MASH (metabolic dysfunction-associated steatohepatitis): resmetirom and semaglutide (Wegovy). However, for pure MASLD (metabolic dysfunction-associated fatty liver disease) without inflammation, there are currently no FDA-approved medications.
How Effective Are Weight Loss Drugs? The Risk and Limitations You Should Know About | EP#422
GLP-1 weight loss drugs are significantly more effective than diet alone, with 90-95% of clinical trial participants losing weight, but real-world non-response rates reach 20%. However, discontinuation rates are high (75% within 18 months), and without proper nutrition and exercise support, users risk losing up to 40% muscle mass while regaining primarily fat, creating sarcopenic obesity.
What Is the MIND Diet? (You Don't Have to Eat Perfectly) | Dr Terry Simpson
The MIND diet combines Mediterranean and DASH diets, focusing on increased fruits, vegetables, legumes, whole grains, and healthy fats while reducing red meat. Dr. Simpson emphasizes that perfection isn't required—studies show people scoring around 12.5 out of 15 points experienced the most benefits.
How Does HeartFlow's AI Analyze Your Heart Scan? | Dr Campbell Rogers | EP#426
Dr. Campbell Rogers explains HeartFlow's AI analysis process for heart scans, emphasizing that the company assesses image quality first, rejecting approximately 2-3% of scans that are too fuzzy. He highlights that scanner type, procedure techniques, and medications used at each site significantly impact image quality and the ability to track disease progression over time.
Muscle Loss Fix: Why Movement Beats More Protein | Simon Hill
Protein is often overemphasized in discussions about muscle loss, but the real driver of sarcopenia in America is sedentary lifestyle and lack of resistance training stimulus. Most people consume sufficient protein; the limiting factor is movement and strength training, not dietary protein intake.